These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34478915)

  • 21. Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.
    Bogstedt A; Groves M; Tan K; Narwal R; McFarlane M; Höglund K
    J Alzheimers Dis; 2015; 46(4):1091-101. PubMed ID: 26402635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study.
    Peters KE; Davis WA; Taddei K; Martins RN; Masters CL; Davis TM; Bruce DG
    J Alzheimers Dis; 2017; 56(3):1127-1133. PubMed ID: 28106562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.
    Ovod V; Ramsey KN; Mawuenyega KG; Bollinger JG; Hicks T; Schneider T; Sullivan M; Paumier K; Holtzman DM; Morris JC; Benzinger T; Fagan AM; Patterson BW; Bateman RJ
    Alzheimers Dement; 2017 Aug; 13(8):841-849. PubMed ID: 28734653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
    Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Between Peripheral Transport Proteins and Plasma Amyloid-β in Patients with Alzheimer's Disease Were Different from Cognitively Normal Controls: A Propensity Score Matching Analysis.
    Gao L; Wang J; Jiang Y; Wei S; Shang S; Chen C; Dang L; Huo K; Deng M; Wang J; Qu Q
    J Alzheimers Dis; 2020; 78(2):699-709. PubMed ID: 33016902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
    Basun H; Nilsberth C; Eckman C; Lannfelt L; Younkin S
    Dement Geriatr Cogn Disord; 2002; 14(3):156-60. PubMed ID: 12218259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease.
    Ghasemi F; Hormozi-Nezhad MR; Mahmoudi M
    Nanoscale; 2018 Apr; 10(14):6361-6368. PubMed ID: 29561053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Long-Term Storage on the Reliability of Blood Biomarkers for Alzheimer's Disease and Neurodegeneration.
    Schubert CR; Paulsen AJ; Pinto AA; Merten N; Cruickshanks KJ
    J Alzheimers Dis; 2022; 85(3):1021-1029. PubMed ID: 34924380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.
    Seppälä TT; Herukka SK; Hänninen T; Tervo S; Hallikainen M; Soininen H; Pirttilä T
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1123-7. PubMed ID: 20478847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of plasma β-amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease.
    Wang D; Dai Y; Wang X; Yu P; Qu S; Liu Z; Cao Y; Zhang L; Ping Y; Liu W; Tao Z
    Mikrochim Acta; 2021 Jan; 188(1):24. PubMed ID: 33404755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
    Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
    Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma amyloid beta levels and platelet mitochondrial respiration in patients with Alzheimer's disease.
    Fišar Z; Jirák R; Zvěřová M; Setnička V; Habartová L; Hroudová J; Vaníčková Z; Raboch J
    Clin Biochem; 2019 Oct; 72():71-80. PubMed ID: 30954436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.
    Ruiz A; Pesini P; Espinosa A; Pérez-Grijalba V; Valero S; Sotolongo-Grau O; Alegret M; Monleón I; Lafuente A; Buendía M; Ibarria M; Ruiz S; Hernández I; San José I; Tárraga L; Boada M; Sarasa M
    PLoS One; 2013; 8(11):e81334. PubMed ID: 24312290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.
    Shaw LM; Hansson O; Manuilova E; Masters CL; Doecke JD; Li QX; Rutz S; Widmann M; Leinenbach A; Blennow K
    Clin Biochem; 2019 Oct; 72():7-14. PubMed ID: 31129181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
    Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
    Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.
    Giedraitis V; Sundelöf J; Irizarry MC; Gårevik N; Hyman BT; Wahlund LO; Ingelsson M; Lannfelt L
    Neurosci Lett; 2007 Nov; 427(3):127-31. PubMed ID: 17936506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical performance and robustness evaluation of plasma amyloid-β
    Rabe C; Bittner T; Jethwa A; Suridjan I; Manuilova E; Friesenhahn M; Stomrud E; Zetterberg H; Blennow K; Hansson O;
    Alzheimers Dement; 2023 Apr; 19(4):1393-1402. PubMed ID: 36150024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Technical Validation of an Immunoassay for the Detection of APP
    Klafki HW; Rieper P; Matzen A; Zampar S; Wirths O; Vogelgsang J; Osterloh D; Rohdenburg L; Oberstein TJ; Jahn O; Beyer I; Lachmann I; Knölker HJ; Wiltfang J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.